RU2022128550A - DRUG DELIVERY SYSTEMS BASED ON MAITANZINOID - Google Patents
DRUG DELIVERY SYSTEMS BASED ON MAITANZINOID Download PDFInfo
- Publication number
- RU2022128550A RU2022128550A RU2022128550A RU2022128550A RU2022128550A RU 2022128550 A RU2022128550 A RU 2022128550A RU 2022128550 A RU2022128550 A RU 2022128550A RU 2022128550 A RU2022128550 A RU 2022128550A RU 2022128550 A RU2022128550 A RU 2022128550A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- compound
- group
- acceptable salt
- optionally substituted
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drugs Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 15
- 239000011780 sodium chloride Substances 0.000 claims 15
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 239000000969 carrier Substances 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 102100001249 ALB Human genes 0.000 claims 2
- 101710027066 ALB Proteins 0.000 claims 2
- 206010006417 Bronchial carcinoma Diseases 0.000 claims 2
- 208000003362 Bronchogenic Carcinoma Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 108020005497 Nuclear hormone receptors Proteins 0.000 claims 2
- 229940050528 albumin Drugs 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 claims 2
- 201000001539 ovarian carcinoma Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000009956 Adenocarcinoma Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N Phloretic acid Chemical group OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 1
- 201000007538 anal carcinoma Diseases 0.000 claims 1
- 125000004069 aziridinyl group Chemical group 0.000 claims 1
- 201000009030 carcinoma Diseases 0.000 claims 1
- 201000003963 colon carcinoma Diseases 0.000 claims 1
- 201000011231 colorectal cancer Diseases 0.000 claims 1
- 125000002228 disulfide group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000003914 endometrial carcinoma Diseases 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229920005615 natural polymer Polymers 0.000 claims 1
- 101700061999 nhr-3 Proteins 0.000 claims 1
- 125000005030 pyridylthio group Chemical group N1=C(C=CC=C1)S* 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- -1 vinylcarbonyl group Chemical group 0.000 claims 1
Claims (40)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/593,184 | 2017-11-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020121456A Division RU2783076C2 (en) | 2017-11-30 | 2018-11-30 | Drug delivery systems based on maytansinoid |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2022128550A true RU2022128550A (en) | 2022-11-25 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Stathopoulos | Liposomal cisplatin: a new cisplatin formulation | |
Awasthi et al. | Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer | |
Mittapalli et al. | Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) | |
Mullauer et al. | Betulinic acid delivered in liposomes reduces growth of human lung and colon cancers in mice without causing systemic toxicity | |
Wu et al. | The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy | |
US10881678B2 (en) | Cytotoxic agents for the treatment of cancer | |
Yang et al. | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor | |
Walczak et al. | Sarcoma chemotherapy | |
WO2020078905A1 (en) | Combination therapy utilizing dna alkylating agents and atr inhibitors | |
Meijer et al. | Lymph node effective vascular permeability and chemotherapy uptake | |
RU2017146346A (en) | COMBINED THERAPY PAC-1 | |
Feliu et al. | Phase II randomised trial of raltitrexed–oxaliplatin vs raltitrexed–irinotecan as first-line treatment in advanced colorectal cancer | |
BR112020023200A2 (en) | compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds for the treatment of adenoid cystic carcinoma | |
JP2016519107A (en) | Predictive and response biomarkers for TH-302 anticancer therapy | |
BR112020022654A2 (en) | COMBINATION COMPOSITIONS THAT UNDERSTAND BISFLUOROALKYL-1,4-BENZODIAZEPINONE COMPOUNDS AND METHODS OF USE THEREOF | |
RU2022128550A (en) | DRUG DELIVERY SYSTEMS BASED ON MAITANZINOID | |
ES2797758T3 (en) | Pharmaceutical composition for the treatment or palliation of elderly or terminally ill cancer patients | |
Goldwasser et al. | Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies | |
RU2678772C2 (en) | Cabazitaxel composition | |
Tomasello et al. | Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial | |
Piatek et al. | Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors | |
Hutson et al. | Subgroup analyses of a phase III trial comparing tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC) | |
Swami et al. | Marine sponge derived eribulin in preclinical and clinical studies for cancer | |
JP2022544832A (en) | METTL16 inhibitors and uses thereof | |
RU2020121456A (en) | DRUG DELIVERY SYSTEMS BASED ON MAITANZINOID |